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Abstract
Background: The efficacy of anti-malarial drugs is determined by the level of parasite susceptibility, anti-malarial
drug bioavailability and pharmacokinetics, and host factors including immunity. Host immunity improves the
in vivo therapeutic efficacy of anti-malarial drugs, but the mechanism and magnitude of this effect has not been
characterized. This study characterized the effects of ‘immune’ plasma to Plasmodium falciparumon the in vitro
susceptibility of P. falciparum to anti-malarial drugs.
Methods: Titres of antibodies against blood stage antigens (mainly the ring-infected erythrocyte surface antigen
[RESA]) were measured in plasma samples obtained from Thai patients with acute falciparum malaria. ‘Immune’
plasma was selected and its effects on in vitro parasite growth and multiplication of the Thai P. falciparum
laboratory strain TM267 were assessed by light microscopy. The in vitro susceptibility to quinine and artesunate was
then determined in the presence and absence of ‘immune’ plasma using the
3H-hypoxanthine uptake inhibition
method. Drug susceptibility was expressed as the concentrations causing 50% and 90% inhibition (IC50 and IC90),
of
3H-hypoxanthine uptake.
Results: Incubation with ‘immune’ plasma reduced parasite maturation and decreased parasite multiplication in a dose
dependent manner.
3H-hypoxanthine incorporation after incubation with ‘immune’ plasma was decreased significantly
compared to controls (median [range]; 181.5 [0 to 3,269] cpm versus 1,222.5 [388 to 5,932] cpm) (p= 0.001). As a result
‘immune’ plasma reduced apparent susceptibility to quinine substantially; median (range) IC50 6.4 (0.5 to 23.8) ng/ml
versus 221.5 (174.4 to 250.4) ng/ml (p = 0.02), and also had a borderline effect on artesunate susceptibility; IC50 0.2
(0.02 to 0.3) ng/ml versus 0.8 (0.2 to 2.3) ng/ml (p = 0.08). Effects were greatest at low concentrations, changing the
shape of the concentration-effect relationship. IC90 values were not significantly affected; median (range) IC90 448.0
(65 to > 500) ng/ml versus 368.8 (261 to 501) ng/ml for quinine (p > 0.05) and 17.0 (0.1 to 29.5) ng/ml versus 7.6
(2.3 to 19.5) ng/ml for artesunate (p = 0.4).
Conclusions: ’Immune’ plasma containing anti-malarial antibodies inhibits parasite development and multiplication
and increases apparent in vitro anti-malarial drug susceptibility of P. falciparum. The IC90 was much less affected
than the IC50 measurement.
Background
Falciparum malaria remains the most important parasite
infection in the tropical world. Development of anti-
malarial drug resistance is a major threat for malaria
control. Early signs of low-grade resistance can be
obscured by anti-malarial immunity. The positive contri-
bution of host immunity to the therapeutic response to
anti-malarial drugs has been recognized for nearly a
century [1]. In endemic areas, protective immunity is
acquired and maintained with repeated exposure to
Plasmodium falciparum and is an important factor
determining therapeutic outcome following anti-malarial
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if tested in semi-immune adults, whilst cure rates in
children from the same area are unacceptable [4]. The
host defence against malaria, which includes pre-
erythrocytic immunity, blood stage immune responses
and augmented splenic clearance function, is still poorly
characterized. Antibody clearly plays a role; for example
increased levels of anti-MSP119 IgG1 were associated
with improved efficacy of sulphadoxine-pyrimethamine
in Gabonese children [5] but the precise contributions
of this and other antibodies to drug efficacy were not
quantitated. Immunity is associated with both augmen-
tation of parasite clearance responses and increased cure
rates. An increase in parasite clearance times after treat-
ment with artesunate-mefloquine combination therapy
on the Thai-Myanmar border after 2002 coincided with
a sharp reduction in malaria transmission in the area
could be explained by lower immunity in this popula-
tion [6]. The quantitative contribution of host immunity
to drug efficacy is difficult to assess, and there are few
studies addressing this ex vivo. The current study quan-
titated the effects of ‘immune’ plasma containing anti-
malarial antibodies on parasite growth and susceptibility
of P. falciparum to quinine and artesunate.
Methods
Malaria parasites
Plasmodium falciparum Thai laboratory strain TM267,
was cultured in malaria culture medium (MCM) supple-
mented with 0.5% Albumax II (Gibco, New Zealand) as
previously described [7]. Parasites were synchronized to
ring stage through treatment with 5% D-sorbitol [8] just
prior to the experiments.
Selection of ‘immune’ plasma
Plasma was obtained from patients with acute
P. falciparum malaria taking part in clinical studies
p e r f o r m e da tt h eH o s p i t a lf o rT r o p i c a lD i s e a s e si n
Bangkok, Thailand approved by the Ethics committee
of the Faculty of Tropical Medicine, Mahidol Univer-
sity. Patients who had no history of anti-malarial drug
treatment before admission were screened for previous
treatment with quinine and mefloquine using dipstick.
Plasma was assessed for the presence of antibodies
against blood stage antigens (mainly ring-infected ery-
throcyte surface antigen [RESA]) by an immunofluor-
escence assay (IFA), as described previously [9]. In
brief, 10 μl of plasma (1:50 v/v in phosphate buffered
saline [PBS]) was applied on an antigen-coated slide,
i n c u b a t e da tr o o mt e m p e r a t u r ef o r3 0m i n u t e s ,a n d
then washed twice with PBS. Five microlitres of rabbit
anti-human IgG conjugated to fluorescein isothiocya-
nate (FITC; DAKO, Denmark) (1:50 v/v in PBS) was
then added to each spot on the antigen-coated slide,
incubated at room temperature for 30 minutes (pro-
tected from light), and then washed twice with PBS.
The slides were counterstained and mounted with
10 μg/ml ethidium bromide (Sigma, USA) in 50% gly-
cerol (Sigma, USA), and then examined under a fluor-
escence microscope (Model BX60; Olympus, Japan).
Plasma reacting positively showed as a coated green
fluorescence on the surface of infected red blood cells.
Plasma positive for blood stage antibodies at a titre
1:50 (v/v) was then further assessed at titres of 1:250
and 1:1,250 (v/v). ‘Immune’ plasma was defined as
plasma containing blood stage antibodies at titre
greater than 1:50. Individual plasma (N = 1) at a titre
of 1:50 was used for the assessment of the effect on
the parasite growth. Plasma at tires of 1:250 (N = 2)
and 1:1,250 (N = 1) were used for the assessment of
the effects on the anti-malarial drug susceptibility.
The plasma samples were then heated at 56°C for
30 minutes and then kept at -20°C until used.
Effects of ‘immune’ plasma containing anti-malarial
antibodies on growth of Plasmodium falciparum
Twenty-five microlitres ofs y n c h r o n i z e dr i n gs t a g e
P. falciparum(TM267), at 1% P. falciparum infected ery-
throcytes with >80% ring stages were incubated with
either 25 μl ‘immune’ plasma containing anti-malarial
antibodies or plasma from healthy subjects at concentra-
t i o n so f2 . 5 % ,5 % ,1 0 % ,2 0 % ,a n d4 0 %( v / vi nM C M )a t
37°C for 48 hours. Parasites incubated with MCM sup-
plemented with 0.5% Albumax II (without ‘immune’
plasma) were included as controls. Parasite growth and
stage of development were assessed by microscopy [10].
Parasite multiplication was then assessed as the percen-
tage of ring-infected red cells in all infected red blood
cells after 48 hours incubation in the presence of
‘immune’ plasma containing anti-malarial antibodies
relative to control (without ‘immune’ plasma). All
experiments were repeated four times.
Drug susceptibility assay
Assessments of parasite growth and anti-malarial drug
susceptibility of P. falciparum TM267 were assessed by
an isotopic assay using tritium [
3H]-hypoxanthine as
described previously [11]. In brief, 50 μl of a 3% haema-
tocrit red cell suspension containing 1% P. falciparum
infected erythrocytes with >80% in the ring stage of
development, was incubated with quinine dihydrochlor-
ide (A.N.B. Laboratories Co., Ltd., Thailand) (range of
concentrations: 7.80-500 ng/ml) and artesunate (Guilin
Pharmaceutical Co., Ltd., China) (range of concentra-
tions: 0.16-10 ng/ml), either in the absence or presence
of 10% (v/v) ‘immune’ plasma containing anti-malarial
antibodies. Parasites were incubated at 37°C until devel-
opment to the trophozoite stage.
3H-hypoxanthine
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Page 2 of 8(25 μl: 0.025 uCi/μl) was then added to each well after
which the plates were incubated at 37°C and 5% CO2
for 24 hours until parasites reached the mature schizont
stage, and then frozen at -80°C. After thawing of the
sample, the lysed cells were transferred to a glass fibre
filter (Wallac, Turku, Finland) using a cell harvester
(Packard Instruments, Meriden, Conn.) and
3H-hypox-
anthine uptake was measured by a scintillation counter
(MicroBeta; Wallac Trilux). Four experiments were
done in duplicate. The measure of drug susceptibility
was the concentration of drug inhibiting
3H-hypox-
anthine uptake by 50% and 90% relative to control (50%
and 90% inhibitory concentrations; IC50 and IC90). The
IC50 and the IC90 values were assessed by fitting a sig-
moid dose response curve using WinNonlin software
version 4.1 (Pharsight Corporation, CA).
Statistical analyses
Statistical analyses was performed using SPSS version
11.5 (SPSS Inc., Illinois, USA). The Mann-Whitney
U test was used for comparing groups with non-
normally distributed data. A p-value ≤ 0.05 was consid-
ered statistically significant.
Results
The effects of ‘immune’ plasma on the growth of
Plasmodium falciparum
Seventy-eight plasma samples from uncomplicated
malaria patients were screened for antibodies against
P. falciparum ring stages antigens using the immuno-
fluorescence assay (IFA). A total of 51 patients (65%)
had plasma containing blood stage antibodies assessed
by IFA, of whom 31 (61%) had a titre of 1:50, 17 (33%)
a titre of 1:250, and 3 (6%) a titre of 1:1,1250. In the
in vitro culture, control plasma from healthy subjects
did not react with infected red blood cells. Parasites
developed completely from ring to schizont stage over a
48 hour time period. The median (range) parasitaemia
after schizogony was 1.6% (1.5-1.7), 1.5% (1.4-1.6), 1.5%
(1.4-1.7), 1.4% (1.3-1.4), and 1.2% (1.0-1.4) in the
presence of 2.5%, 5%, 10%, 20%, and 40% (v/v) normal
plasma, respectively (Table 1). Growth was significantly
inhibited (p ≤ 0.05) by concentrations of normal plasma
≥20% but not by lower concentrations. Parasite growth
was inhibited more after incubation with ‘immune’
plasma. In the presence of ‘immune’ plasma (titre of
1:50) at 2.5%, 5%, 10%, 20%, and 40% (v/v), the corre-
sponding parasitaemia was 1.7% (1.2-2.1), 1.4% (0.7-1.4),
1.1% (0.9-1.2), 1.1% (0.5-1.2), and 0.9% (0.7-1.2), respec-
tively. The parasitaemia after incubation with 10%, 20%,
and 40% ‘immune’ plasma were all significantly reduced
compared to control (p < 0.05) (Table 1). Thus, the
median (range) number of ring infected red cells after
schizogony was reduced by 8.2% (0-26.3), 40.3%
(0-70.3), 74.5% (33.3-83.1), 80% (57.1-100), and 93.9%
(75-100) in the presence of 2.5%, 5%, 10%, 20%, and
40% ‘immune’ plasma, respectively (p for trend = 0.001).
The absolute
3H-hypoxanthine uptake after incubation
with 10% ‘immune’ plasma was markedly lower com-
pared to control (median [range]; 181.5 [0-3,269] cpm
versus 1,222.5 [388-5,932] cpm; p=0 . 0 0 1 )( F i g u r e1 ) .
Thus, ‘immune’ plasma inhibited parasite growth and
the development from ring to schizont stages and also
inhibited the multiplication of P. falciparum.
Effects of ‘immune’ plasma on the in vitro measurement
of anti-malarial drug susceptibility
The susceptibility of P. falciparum to the anti-malarial
drugs quinine and artesunate, either in the presence or
absence of 10% ‘immune’ plasma is shown in Figure 2. In
the presence of ‘immune’ plasma (titres of 1:250 and
1:1,250), hypoxanthine uptake was markedly reduced at
lower drug concentrations (Figure 3). The median
(range) derived IC50 values for quinine in the presence
and absence of ‘immune’ plasma were 6.4 (0.5-23.8) ng/
ml and 221.5 (174.4-250.4) ng/ml, respectively (p = 0.02).
The corresponding median (range) derived IC90 values
for quinine were not significantly different; 448.0
Table 1 Plasmodium falciparum parasitaemia in culture in the presence of plasma from healthy donors and ‘immune’
plasma
Plasma concentration Median (range) % parasitaemia after 48 hours incubation *
Normal plasma ‘Immune’ plasma **
Control (MCM) 1.7 (1.5-2.6) 1.7 (1.4-2.3)
2.5% 1.6 (1.5-1.7) 1.7 (1.2-2.1)
5% 1.5 (1.4-1.6) 1.4 (0.7-1.4)
10% 1.5 (1.4-1.7) 1.1 (0.9-1.2) ***
20% 1.4 (1.3-1.4) *** 1.1 (0.5-1.2) ***
40% 1.2 (1-1.4) *** 0.9 (0.7-1.2) ***
*- The percentage of infected red blood cells counted per 1,000 red blood cells.
**- ‘Immune’ plasma (titre of 1:50).
***- Significant difference compared to control; p ≤ 0.05 (N = 4). MCM is malaria culture medium.
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Page 3 of 8(65->500) ng/ml and 368.8 (261-501) ng/ml, respectively
(p > 0.05). The median (range) derived IC50 values for
artesunate in the presence and absence of ‘immune’
plasma were 0.2 (0.02-0.3) ng/ml and 0.8 (0.22-2.29) ng/
ml, respectively (p = 0.08). The corresponding median
(range) derived IC90 values for artesunate were not signif-
icantly different: 17.0 (0.1-29.5) ng/ml and 7.6 (2.3-19.5)
ng/ml, respectively (p = 0.4).
Discussion
Assessing anti-malarial resistance in patients living in
malaria endemic regions of the world is hampered by
the presence of host immunity, which can act as an
important confounder [1]. Early resistance can thus go
unnoticed, because host immunity assists the drug in
parasite clearance. Conversely, waning immunity in a
population with a reduction in malaria transmission can
cause a false impression of reduced drug efficacy.
Exactly which immunological factors are important in
enhancing anti-malarial drug efficacy remains unclear.
The current study investigated the role of ‘immune’
plasma containing anti-malarial antibodies in an in vitro
growth system and standard sensitivity drug assay. The
study confirms earlier studies and the experience of
malariologists conducting in vitro susceptibility testing
that ‘immune’ plasma significantly inhibits the develop-
ment of P. falciparum from the ring to schizont stage of
development and also inhibits parasite multiplication.
The mechanism of action of antibodies is not well
understood. Antibodies are thought to reduce parasite
multiplication through interference with merozoite inva-
sion (e.g. through anti-MSP-1 [12] and anti-EBA-175
antibodies [13]) and with intraerythrocytic development
[14] (e.g. through anti-RESA [15-18] and anti-PfEMP-1
antibodies [19]). How they impair growth is poorly
understood. Anti-RESA antibodies have been shown
previously to inhibit parasite growth [15-17] and multi-
plication [18] and they can be used as markers of the
broader humoral immune response [20]. Anti-MSP-1
antibodies have been shown to prevent the processing
of merozoite surface proteins [12] and anti-EBA-175
antibodies have been proposed to interfere with the
recognition of erythrocyte ligands, both involved in the
invasion process [13]. Antibodies to PfEMP-1 aggluti-
nate infected RBCs, and through this mechanism are
thought to inhibit merozoite invasion and parasite mul-
tiplication [19].
In addition to anti-malarial antibodies, plasma obtained
from patients with an acute falciparum malaria infection
also contains other factors which inhibit parasite growth.
Acute phase proteins such as C-reactive protein, a1-acid
glycoprotein, mannose-binding protein, and complement
may affect the multiplication of P. falciparum.I th a s
been proposed that a1-acid glycoprotein inhibits parasite
multiplication by interfering with parasite-erythrocyte
interactions during the invasion process [21]. C-reactive
protein has been proposed to prevent the penetration
of sporozoites into hepatocytes and to inhibit parasite
replication during pre-erythrocytic development [22].
Mannose-binding protein (MBP) can initiate the lectin
complement pathway eventually leading to cell lysis [23].
In the present study, inactivated plasma by heating at
56°C for 30 minutes was used in the experiments.
Through this procedure proteins of the complement
system lost their enzymatic activity [24] and therefore,
complement factors and MBP were unlikely to have
interfered with parasite development in the current
study. The study also addressed the effects of non-
specific proteins in plasma from normal donors on para-
site development. Normal plasma showed no effect in
concentrations up to 10% (v/v), but did inhibit parasite
growth in higher concentrations of 20% and 40% (v/v).
For this reason, a 10% plasma concentration (v/v) was
used for the assessment of the effect of ‘immune’ plasma
in the anti-malarial drug sensitivity assays. We found that
plasma containing anti-malarial antibodies significantly
increased the apparent susceptibility of P. falciparum to
quinine and also had a borderline effect on artesunate.
These effects were greater at low drug concentrations
distorting the normal sigmoid shape of the concentra-
tion-effect relationship. IC50 values for quinine were
markedly altered whereas IC90 values were not affected
significantly. As IC50 values are usually reported, these
3H-hypoxanthine uptake (cpm)
'Immune' plasma Control
8,000
6,000
4,000
2,000
0
*
3H-hypoxanthine uptake (cpm)
'Immune' plasma Control
8,000
6,000
4,000
2,000
0
*
Figure 1 Plasma from acute malaria inhibits
3H-hypoxanthine
uptake by Plasmodium falciparum. Parasites were incubated in
malaria culture medium with 10% (v/v) ‘immune’ plasma containing
anti-malarial antibodies for 48 hours. Parasite uptake of
hypoxanthine (in counts per minute; cpm) is shown as the median
values with 25
th and 75
th percentiles and ranges from 4
experiments in duplicate. Control parasites were incubated in
culture medium with 10% plasma from healthy donors.
* p ≤ 0.05
(Mann-Whitney U test).
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Figure 2 The dose-response curve of P. falciparum anti-malarial drug susceptibility. Parasites were incubated with A) quinine without
‘immune’ plasma (white circle) and quinine with 10% ‘immune’ plasma (black circle) (range: 7.80-500 ng/ml); and B) artesunate without
‘immune’ plasma (white square) and artesunate with 10% ‘immune’ plasma (black square) (range: 0.16-10 ng/ml). The percentage of
3H-
hypoxanthine uptake was plotted against drug concentrations. The dotted lines represent 50% and 90% inhibition. Data are shown as the
median values and interquartile ranges from 4 experiments.
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sequent population reduction in malaria antibody titers
might lead to a rise in IC50 values of fresh isolates.
This could be mistaken as indicating increasing resis-
tance. The effects of ‘immune’ plasma on quinine IC50
values were much greater than on artesunate. The stage-
specificity of the effect of anti-malarial antibodies might
explain this difference. If antibodies recognize antigenic
determinants on more mature trophozoites and therefore
act predominantly at that stage, then they may have a
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Figure 3 Modulating effects of ‘immune’ plasma containing anti-malarial antibodies on in vitro P. falciparum anti-malarial drug
susceptibility. The magnitude of the effect of ‘immune’ plasma on the susceptibility to A) quinine (black circle) and B) artesunate (black
square) expressed as the percentage of
3H-hypoxanthine uptake without ‘immune’ plasma subtracted to that of drug combined with 10%
‘immune’ plasma containing anti-malarial antibodies. Data are shown as the median values and interquartile ranges from 4 experiments.
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Page 6 of 8greater effect in synergistically with drugs, which act only
at this stage. Quinine acts predominantly on mature
parasites whereas artesunate has a broad stage-specificity
and acts on both young and mature stages. Future studies
to characterize and assess the factors in ‘immune’ plasma
which interfere specifically with parasite growth are
required.
Conclusions
‘Immune’ plasma containing anti-malarial antibodies
inhibits intraerythrocytic development of P. falciparum
as well as parasite multiplication in an in vitro growth
system. ‘Immune’ plasma increased in vitrosusceptibility
to quinine and also had a borderline effect on artesunate
susceptibility. Effects were greater at low drug concen-
t r a t i o n s ,s ot h eI C 50was affected much more than the
IC90 estimates.
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